# US 2023/0265141 A1 · Preparation method and use of double-target fusion protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265141 A1
- Document ID: US20230265141A1
- Status: Published application
- Kind: A1
- Application number: 18/181,666
- Filed: 2023-03-10
- Published: 2023-08-24
- Earliest claimed: 2021-04-30
- Assignees: Jiangnan University
- Applicants: Jiangnan University
- Inventors: Shenglong Zhu; Yongquan Chen; Zhen Wang
- Web page: https://patentgrep.com/patent/US20230265141A1

## CPC

- C07K 14/50: Fibroblast growth factor [FGF]
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/26: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/605: Glucagons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.

## Claims

### Claim 1

A fusion protein, comprising R1-R2 or R1-L-R2,
wherein R1 is a human fibroblast growth factor FGF19 protein, R2 is a glucagon-like peptide-1, and L is a linker peptide; and
the FGF19 protein has the amino acid sequence as set forth in any one of SEQ ID NO. 1-3; and the glucagon-like peptide 1 has the amino acid sequence as set forth in SEQ ID NO. 4.

### Claim 2 (depends on 1)

A drug for treating hepatitis or a related disease comprising the fusion protein of claim 1, wherein the fusion protein is used as an effective component; and the treating hepatitis or a related disease comprises reducing liver weight and the content of liver triglycerides, repairing liver damage, and relieving nonalcoholic steatohepatitis, atherosclerosis, liver damage, primary biliary cholangitis, and/or primary sclerosing cholangitis.

### Claim 3 (depends on 1)

A drug for improving insulin sensitivity and regulating blood sugar comprising the fusion protein of claim 1, wherein the fusion protein is used as an effective component.
